Treatment-resistant thrush: why it won't clear

Author: Jessica Lloyd
Senior Vulvovaginal Speciliast Naturopath | BHSc(N) | ISSVD, ISSWSH, BSSM, ATMS

Last reviewed: June 24, 2026

If your thrush keep coming back, or a standard antifungal cream or tablet simply hasn’t touched it, you may be dealing with treatment-resistant thrush. The problem may not be your treatment habits. It may be the species you are carrying.

A new study published in Infection and Drug Resistance tested 42 rare yeast isolates from women with vulvovaginal candidiasis (VVC) and found that, at realistic vaginal pH, several common antifungals lose a noticeable amount of their punch.¹

In short, when a yeast infection is caused by something other than Candida albicans, the drug that usually works may not, and the only way to know which species you have is a proper culture or PCR test.

In our clinical experience here at My Vagina, we see people who have been through round after round of antifungals with no lasting result. Very often, nobody has ever identified the actual yeast – treatment has been based on symptoms or basic analysis. This study helps explain why comprehensive testing matters so much.

Why some yeast infections won’t clear with standard treatment

Most thrush is caused by Candida albicans, which usually responds well to the azole antifungals people are handed at the pharmacy or by a GP. But roughly a third of vaginitis cases are caused by Candida, and a growing share of those are non-albicans species.^1,2

Some are well known, such as Nakaseomyces glabratus (the yeast many people still call Candida glabrata) and Candida krusei. Others are genuinely rare. These rarer, non-albicans yeasts are the usual story behind treatment-resistant thrush.

The researchers, working in a hospital gynaecology clinic, collected uncommon vaginal yeasts over a year and identified them by sequencing their DNA. They found 11 different rare species, led by Saccharomyces cerevisiae (the same genus as baker’s and brewer’s yeast), Clavispora lusitaniae, and a smattering of others including Kodamaea ohmeri, Pichia norvegensis, Candida metapsilosis and two relatives of C. glabrata.¹

These yeasts are not unusual in the environment or on the skin. The problem is that we have very little data on how to treat them, and laboratories have not yet agreed on what counts as resistant for most of them.¹

The acidic vagina changes how antifungals behave

Here is the part that should change how we think about treatment. Standard lab susceptibility testing is done at a neutral pH of 7.0. But the vagina stays broadly acidic during a yeast infection, typically around pH 4 to 4.5, in contrast to the rise seen in bacterial vaginosis. An antifungal judged ‘susceptible’ on a neutral-pH lab report may behave quite differently in that acidic environment.^1,3,4

That acidity is not completely fixed, though. In practice the bulk vaginal reading can sit a little higher than the textbook figure – in one cohort, women with acute infection averaged around pH 4.7 – and mixed infections can nudge it up further.⁷

Candida albicans can also actively raise the pH of its own immediate surroundings, extruding ammonia as it switches from a rounded yeast cell to its invasive, thread-like hyphal form.⁶ So the acidity is real and broadly stable, but it is neither static nor uniform – the yeast itself works to neutralise its microenvironment as it turns invasive.

When the team retested the same yeasts at the realistic acidic pH of 4.5, several drugs became markedly less active. Terconazole was hit hardest, with the concentration needed to control the yeast rising sharply for almost every isolate. Amphotericin B and nystatin also lost ground at acidic pH, as did one of the echinocandins, micafungin.¹

Some agents held up well. Fluconazole, voriconazole, miconazole and clotrimazole were among the least affected by the lower pH, and 5-flucytosine, anidulafungin and caspofungin barely changed at all.¹

In other words, a yeast can look perfectly treatable on a lab report, then shrug off the same drug in the acidic place it actually lives. The authors are blunt about it: clinicians should recognise the limits of susceptibility testing done at neutral pH.¹

Different species, different weak spots

The study’s most useful message is that susceptibility is both drug-specific and genus-specific. The species you have genuinely changes which treatment is likely to work.¹

Saccharomyces cerevisiae was the steadiest, staying susceptible to most agents, though terconazole, amphotericin B and nystatin weakened against it at acidic pH.
Clavispora lusitaniae is long known for clinical failures with amphotericin B despite looking sensitive on paper, and at acidic pH its susceptibility to several drugs dropped further.
The two Nakaseomyces relatives of C. glabrata were the most affected by acidity across every azole tested, though they stayed within the susceptible range.
Kodamaea ohmeri and Pichia norvegensis showed raised fluconazole readings, fitting their reputation as awkward, azole-tolerant species.

The authors argue that knowing which clade a yeast belongs to gives a first clue to how it will behave, which is a sensible starting point when formal treatment guidelines for these species simply don’t exist yet.^1,5

What this means for treatment-resistant thrush

If you have been treating what looks like thrush again and again with the same product and getting nowhere, this is the picture of treatment-resistant thrush – and a strong argument for stopping the guesswork and finding out what you are actually dealing with.

In our experience here at My Vagina, treatment-resistant thrush is very often a story of a misidentified species, or no identification at all. A symptom-based diagnosis cannot tell C. albicans apart from a rare yeast that needs an entirely different drug, dose or duration.

With treatment-resistant thrush, species identification through culture or PCR is the step that changes the picture. It tells you whether you are dealing with ordinary albicans thrush or something like Candida parapsilosis or one of the rarer yeasts above, and it lets a clinician choose a treatment with a realistic chance of clearing it. It also explains why two people with identical symptoms can have completely different outcomes on the same cream.

This is also a reminder that good treatment is about more than reaching for the strongest antifungal. It means matching the drug to the organism, and supporting the protective vaginal bacteria that keep yeast in check in the first place.

Frequently asked questions

Is non-albicans yeast more dangerous?

Not necessarily more dangerous, but often harder to clear. Species such as Nakaseomyces glabratus, Candida krusei and the rarer yeasts in this study can be naturally less responsive to the antifungals used for ordinary yeast infections, so infections drag on or recur as treatment-resistant thrush.¹

How do I find out which yeast I have?

If you have treatment-resistant thrush, you need a laboratory test that identifies the species, either a fungal culture or a PCR or NGS test. A standard swab that only says ‘yeast present’ or a symptom-based diagnosis cannot tell the species apart, so ask specifically for species-level identification.

Why did my lab report say the yeast was susceptible when the treatment failed?

Because most susceptibility testing is done at a neutral pH, not the acidic pH of the vagina. This study found several antifungals lose activity at acidic pH, so a ‘susceptible’ result on paper does not always translate into a cure in real life.¹

Which antifungals held up best in acidic conditions?

In this in vitro study, fluconazole, voriconazole, miconazole, clotrimazole, 5-flucytosine, anidulafungin and caspofungin were least affected by acidic pH. Terconazole, amphotericin B, nystatin and micafungin lost the most activity. These are laboratory findings, not a prescription, and treatment must be individualised by a clinician.¹

Could my recurrent thrush actually be something else entirely?

Yes. Symptoms that look like yeast can also come from aerobic vaginitis, irritation, sensitivity or a mixed picture. People sometimes cycle between yeast and other conditions. If you keep getting yeast-like symptoms with negative or unhelpful tests, check our piece on cycling between yeast and BV and pushing for proper testing.

What to do next

If you have recurrent or treatment-resistant thrush, the single most useful step is to get the species identified rather than repeating the same treatment on guesswork. Start with our guide to getting a thorough PCR or NGS test, which explains what to ask for and why it matters.

If your results are confusing or seem to contradict each other, our explainer on why vaginal tests disagree may help you make sense of them before your next appointment.

You can also ask Aunt Vadge’s Assistant, the chat widget in the bottom left of your screen, to point you to the right information, and from there book a consultation with one of our practitioners if you would like personalised guidance.

This is general information, not a substitute for personalised medical advice. If you have recurrent or treatment-resistant symptoms, please see a qualified clinician who can identify the organism and tailor treatment to you.